Senseonics (NYSE:SENS) CFO Frederick Sullivan Acquires 5,415 Shares of Stock

Senseonics Holdings, Inc. (NYSE:SENS) CFO Frederick Sullivan acquired 5,415 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The shares were bought at an average price of $5.88 per share, with a total value of $31,840.20. Following the completion of the transaction, the chief financial officer directly owned 157,028 shares in the company, valued at approximately $923,324.64. The trade was a 3.57% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Senseonics Trading Up 9.1%

Shares of SENS stock opened at $6.56 on Monday. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. Senseonics Holdings, Inc. has a fifty-two week low of $5.00 and a fifty-two week high of $28.00. The firm’s 50 day moving average price is $8.43 and its two-hundred day moving average price is $9.91. The stock has a market cap of $267.17 million, a price-to-earnings ratio of -49.22 and a beta of 0.79.

Wall Street Analysts Forecast Growth

SENS has been the subject of several analyst reports. Stifel Nicolaus initiated coverage on Senseonics in a report on Tuesday, October 21st. They set a “hold” rating and a $9.00 target price for the company. Barclays reaffirmed an “overweight” rating and set a $31.00 price objective (up from $1.50) on shares of Senseonics in a research note on Wednesday. Lake Street Capital raised shares of Senseonics to a “strong-buy” rating in a research report on Thursday, July 17th. HC Wainwright upped their price target on shares of Senseonics to $18.50 and gave the company a “buy” rating in a research report on Thursday. Finally, TD Cowen lowered their price objective on shares of Senseonics from $25.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $22.70.

Hedge Funds Weigh In On Senseonics

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of Senseonics by 2.2% in the 3rd quarter. Vanguard Group Inc. now owns 34,219,484 shares of the company’s stock valued at $14,920,000 after buying an additional 749,453 shares in the last quarter. Keynote Financial Services LLC lifted its holdings in Senseonics by 1.5% during the 3rd quarter. Keynote Financial Services LLC now owns 211,350 shares of the company’s stock valued at $92,000 after purchasing an additional 3,065 shares during the last quarter. Smith Salley Wealth Management boosted its stake in Senseonics by 10.9% in the 3rd quarter. Smith Salley Wealth Management now owns 61,000 shares of the company’s stock valued at $27,000 after purchasing an additional 6,000 shares during the period. Goldstone Financial Group LLC acquired a new stake in shares of Senseonics in the third quarter valued at approximately $52,000. Finally, HBK Sorce Advisory LLC bought a new stake in shares of Senseonics during the 3rd quarter worth approximately $39,000. 12.36% of the stock is currently owned by institutional investors and hedge funds.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.